Scientific and educational activities

EHA Lymphoma Group Annual Meeting

Date and location: 19-20 September 2025, Uppsala, Sweden
Chairs: Igor Aurer, Ingrid Glimelius.
Activities: Current and new projects were discussed.

11th ELI Workshop: When lymphoma hits the mediastinum

Date and location: 18-19 September 2025, Uppsala, Sweden
Chairs: Marc Andre, Ingrid Glimelius, Sirppa Leppa

Annual meeting of the European MCL Network

Date and location: 2-4 October 2025, Zadar, Croatia
Chair: Martin Dreyling

Clinical trials promoted by or involving the SWG

Dr Nijland—Elderly study in DLBCL.

Collaborations on international projects promoted by or involving the SWG

  • Applying the simplified geriatric assessment to treatment of DLBCL and HL, collaboration with the Fondazione Italiana Linfomi (Merli, Luminari et al)
  • LUPIAE prospective registry in relapsed and refractory FL, developed by the EHA LyG and delivered in collaboration with 11 countries in Europe and the UK (Tonino et al)
  • International T cell project 2.0 (TCP2.0) and sub-studies (DANTE, Virtual Review, MATURE and PET) developed by the EHA LyG and delivered in collaboration with 8 countries in Europe, US, South America and India (Skrypets, Federico, Luminari, Stepanishyna, Manni, Ahearne, Gru, Lückemeier et al)
  • HIV lymphoma registry (NCT05231135) and international guidelines developed by an EHA LyG-ESMO collaboration involving 6 countries in Europe and the UK (Hentrich et al)
  • PET in MZL (PIMENTO study), a FIL/IELSG/French study delivered in partnership with the EHA LyG across 3 European countries (Luminari et al)
  • The Burkitt Lymphoma Network (burkitt-lymphoma.org), an international consortium established 2022 (Chamuleau et al)
  • PLATO, the Posttransplant Disorders Project, a registry developed in collaboration between South American and European hematologists to enhance our understanding of clinical characteristics and outcomes of PTLDs (Pin-Chuen-Zing, Skrypets, Shotton, Stepanishyna).
  • Hodgkin Lymphoma in Older Patients- A Retrospective Study (Collins, Barrett)
  • CNS relapse in DLBCL (Klanova, Trneny)
  • An international multicenter observational retrospective study on Plasmablastic Lymphoma patients (PLALY) (Castellino, Ravano).
  • Patients’ characteristics and treatment outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma following second and subsequent lines of therapy: a real-world data analysis in new drugs era – REALE, a FIL study (Dogliotti).
  • Management of polyneuropathy during BV+AVD treatment, POLY-BVAVD, a PLRG study (Zaucha et al).

Translational work promoted by or involving the SWG

  • Unraveling the Biological Landscape of Hodgkin Lymphoma in Older Patients – SWG on Aging in Hematology and EHA Lymphoma Group. PI – Dr. Paul J. Bröckelmann, Germany. Supported by an EHA research grant.
  • Secondary leukemogenesis in the context of T-cell-based immunotherapies – SWG on Immune therapies. PI – Dr. Johannes Waldschmidt et al., Germany. Supported by an EHA research grant.
  • DANTE (Dynamic Assessment of circulating tumor DNA in T-cell Lymphoma), an international T cell project 2.0 sub-study (Ahearne et al).
  • PET evaluation in PTCLs and its prognostic role: an international multicenter analysis by the TCP2.0 (Luminari et al)
  • FIL_ELDHL (Prospective study on elderly (≥ 65 years) patients affected with classical Hodgkin Lymphoma undergoing Comprehensive Geriatric Assessment at diagnosis), embedded translational research validating the prognostic role of PET2, evaluating TMA biomarkers and assessing the role of immune senescence
Share